JMP Securities analyst Liisa Bayko noted that Achillion's oral factor D inhibitor studies have been slow to enroll due to limited trial sites, but the company plans to update investors on its oral factor D portfolio this coming Monday, which she believes has the potential to renew interest in the stock. She is looking for updated data from first-gen oral factor D inhibitor ACH-4471 from four ongoing studies and the first Phase 1 data from next-gen factor D inhibitors, ACH-5228 and ACH-5548, adding that data that support activity in the C3G indication or in PNH "could reinvigorate interest." Bayko, who sees a blockbuster opportunity for an oral product in this category, keeps an Outperform rating and $10 price target on Achillion shares.